Psychiatric disorders and hyperthyroidism
Keywords:
psychiatric disorders, hyperthyroidism, thyroid hormonesAbstract
Thyroid hormones have the fundamental importance in the development and functioning of the nervous system. Various types of mental disorders and psychopathological symptoms may occur in addition to common hyperthyroidism symptoms associated with hormonal disturbances. People with hyperthyroidism in comparison to euthyroid persons often exhibit characteristics of neuroticism, report more somatic complaints and they are more likely to adopt a defensive position.
Hyperthyroidism can occur with symptoms of affective imbalance of life, manifesting the emotional instability, increased excita-bility, anxiety, sleep disorders as insomnia, quick temper, sensitivity to noise and other symptoms resembling hypersthenic form of neurasthenia in old classification. In everyday clinical practice depressive disorders, which occur even in fourth patient with undiagnosed hyperthyroidism, may be the reason for family doctor advice. Other symptoms that can be observed among people with hyperthyroidism include: anxiety, mood disorders, emotional instability, intellectual impairment and mania. Thyroid disorders are often the cause of affective disorders with bipolar symptomatology. There were reported some psychotic syndromes, such as delirium syndrome, amentic, catatonic, paranoid and mixed disturbances in thyreotoxicosis. Psychiatric consultation should be planned and psychologist care should be provided for patients diagnosed with hyperthyroidism and accompanying psychiatric symptoms. The level of thyroid hormones should be measured to exclude thyreological cause in patients, in whom a clinical study found the occurrence of mental disorders, and psychopathology. In order to monitor the treatment of patients with hyperthyroidism various questionnaires and scales evaluating for example quality of life, anxiety or depressive symptoms may be useful.
References
1. Jarząb B., Lewiński A., Płaczkiewicz-Jankowska E. Choroby tarczycy. W: Szczeklik A. red., Choroby wewnętrzne. Stan wiedzy na rok 2010. Kraków: Medycyna Praktyczna; 2010, s. 1091-1142.
2. Morreale de Escobar G., Obregon M.J., Escobar del Rey F. Role of thyroid hormone during early brain development. Eur. J. Endocrinol., 2004; 151(Suppl 3): U25-37.
3. Leonard J.L. Non-genomic actions of thyroid hormone in brain development. Steroids, 2008; 73: 1008-1012. 4. Farwell A.P., Dubord-Tomasetti S.A., Pietrzykowski A.Z., Stachelek S.J., Leonard J.L. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3',5'-triiodothyronine. Brain Res. Dev. Brain Res., 2005; 154: 121-135.
5. Vincent J., Legrand C., Rabié A., Legrand J. Effects of thyroid hormone on synaptogenesis in the molecular layer of the developing rat cerebellum. J. Physiol. (Paris), 1982-1983; 78: 729-738.
6. Trentin A.G. Thyroid hormone and astrocyte morphogenesis. J. Endocrinol., 2006; 189: 189-197.
7. Noguchi T. Effects of growth hormone on cerebral development: morphological studies. Horm. Res., 1996; 45: 5-17.
8. Fekete C., Lechan R.M. Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: role of neuronal afferents and type 2 deiodinase. Front. Neuroendocrinol., 2007; 28: 97-114.
9. de Escobar G.M., Ares S., Berbel P., Obregón M.J., del Rey F.E. The changing role of maternal thyroid hormone in fetal brain development. Semin. Perinatol., 2008; 32: 380-386.
10. Obregon M.J., Escobar del Rey F., Morreale de Escobar G. The effects of iodine deficiency on thyroid hormone deiodination. Thyroid, 2005; 15: 917-929.
11. Hernandez A., Martinez M.E., Fiering S., Galton V.A., St Germain D. Type 3 deiodinase is critical for the maturation and function of the thyroid axis. J. Clin. Invest., 2006; 116: 476-484.
12. Hernandez A., Quignodon L., Martinez M.E., Flamant F., St Germain D.L. Type 3 deiodinase deficiency causes spatial and temporal alterations in brain T3 signaling that are dissociated from serum thyroid hormone levels. Endocrinology, 2010; 151: 5550-5558.
13. Lewin-Kowalik J., Gołka B., Larysz-Brysz M., Swiech-Sabuda E., Granek A. Experimental hyperthyroidism increases the effectiveness of predegenerated peripheral nerve graft implantation into hippocampus of adult rats. Restor. Neurol. Neurosci., 2002; 20: 181-187.
14. McDeemott M. Endocrine Secrets. Mosby: Elsevier 6th ed.; 2009.
15. Davies T.F. Graves’ disease: pathogenesis. W: Braverman L.E., Utiger R.D. red., Werner&Ingbar’s thyroid: a fundamental and clinical text. 8th ed. Philadelphia 7 Lippincott Williams &Wilkins; 2000; s. 518-531.
16. Busuttil B.E., Frauman A.G. Extrathyroidal manifestations of Graves’disease: the thyrotropin receptor is expressed in extra ocular, but not cardiac muscle tissues. J Clin Endocrinol Metab, 2001;86: 2315-2319.
17. Crisanti P., Omri B., Hughes E.J. i wsp. The expression of thyrotropin receptor in the brain. Endocrinology, 2001;142:812-822.
18. Saunier B., Pierre M., Jacquemin C., Courtin F. Evidence for cAMPindependent thyrotropin effects on astroglial cells. Eur. J. Biochem., 1993;2418:1091-1094.
19. Koehrle J. Local activation and inactivation of thyroid hormones: the deiodinase family. Mol Cell Endocrinol, 1999;151:103-119.
20. Bunevicius R., Velickiene D., Arthur J. Prange Jr., M.D. Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves’ disease. Gen. Hosp. Psychiatry, 2005;27, 133-139.
21. Kaplan H.I., Sadock B.J., Grebb J.A. Kaplan and Sadock's Synopsis of Psychiatry Behavioral Sciences - Clinical Psychiatry. Williams and Wilkins: 1994.
22. Haggerty Jr J.J., Prange Jr A.J. Borderline hypothyroidism and depression. Annu. Rev. Med., 1995; 46: 37-46.
23. Duval F., Mokrani M.C., Lopera F.G., Diep T.S., Rabia H., Fattah S. Thyroid axis activity and suicidal behavior in depressed patients. Psychoneuroendocrinology, 2010; 35: 1045-1054.
24. Placidi G.P.A. Boldrini M., Patronelli A., Fiore E., Chiovato L., Perugi G., Marazziti D. Prevalence of psychiatric disordres in thyroid diseased patients. Neuropsychobiol., 1998; 38: 222-225.
25. Fahrenfort J.J., Wilterdink A.M., van der Veen E.A. Long-term residual complaints and psychosocial sequelae after remission of hyperthyroidism. Psychoneuroendocrinology, 2000; 25: 201-211.
26. Kathol R.G., Delahunt J.W. The relationship of anxiety and depression to symptoms of hyperthyroidism using operational criteria. Gen. Hosp. Psychiatry, 1986; 8: 23-28.
27. Peake R.L. Recurrent apathetic hyperthyroidism. Arch. Intern. Med., 1981; 141: 258-260.
28. Lifschytz T., Goltser-Dubner T., Landshut G., Lerer B. Effect of triiodothyronine on 5-HT1A and 5-HT1B receptor expression in rat forebrain and on latency to feed in the novelty suppressed feeding test. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010; 30: 632-638.
29. Sandrini M., Vitale G., Vergoni A.V., Ottani A., Bertolini A. Effect of acute and chronic treatment with triiodothyronine on serotonin levels and serotonergic receptor subtypes in the rat brain. Life Sci., 1996; 58: 1551-1559.
30. Eitan R., Landshut G., Lifschytz T., Einstein O., Ben-Hur T., Lerer B. The thyroid hormone, triiodothyronine, enhances fluoxetine-induced neurogenesis in rats: possible role in antidepressant-augmenting properties. Int. J. Neuropsychopharmacol., 2010; 13: 553-561.
31. Bilikiewicz A. Psychiatria. Podręcznik dla studentów medycyny. Wydanie II. Warszawa: Wydawnictwo Lekarskie PZWL; 1998.
32. Rizvi A.A."Thyrotoxic psychosis" associated with subacute thyroiditis. South Med. J. 2007; 100(8): 837-840.
33. Suwalska A., Łojko D. Zaburzenia psychiczne w chorobach endokrynnych i ich leczenie. Terapia, 2004; 12, 25-29.
34. Giętka-Czernel M., Jastrzębska H. Rozpoznawanie i leczenie chorób tarczycy. Warszawa: Ośrodek Informacji Naukowej „Polfa”; 2002.
35. Demet M.M., Ozmen B., Deveci A., Boyvada S., Adigüzel H., Aydemir O. Depression and anxiety in hyperthyroidism. Arch. Med. Res., 2002; 33: 552-556.
36. MacCrimmon D.J., Wallace J.E. Goldberg W.M., Streiner D.L. Emotional disturbance and cognitive deficits in hyperthyroidism. Psychosomatic Med., 1979; 41: 331-340.
37. Suwalska A., Łojko D., Rybakowski J. Schorzenia neuroendokrynne a zaburzenia funkcji poznawczych. Część II: Rola dysfunkcji tarczycy. W: Borkowska A, red. Zaburzenia funkcji poznawczych w chorobach psychicznych. Kraków: Biblioteka Psychiatrii Polskiej; 2005, s. 63-71.
38. Fukui T. Hasegawa Y., Takenaka H. Hyperthyroid dementia: clinicoradiological findings and response to treatment. J. Neurol. Sci., 2001; 1: 81-88.
39. Munte T.F. Radamm C, Johannes S, Brabant G.Alterations of cognitive functions induced by exogenous application of thyroid hormones in healthy men: a double-blind cross-over study using event-related brain potentials. Thyroid, 2001; 4: 385-391.
40. Jabłkowska K., Karbownik-Lewińska M., Nowakowska K., Junik R., Lewiński A., Borkowska A. Working memory and executive functions in hyperthyroid patients with Graves' disease. Psychiatr. Pol., 2008; 42: 249-259.
41. Kopell B.S., Wittner W.K., Lunde D., Warrick G., Edwards D. Influence of triiodothyronine on selective attention in man as measured by the visual averaged evoked potential. Psychosomatic Med., 1970; 3: 495-502.
42. Łojko D., Suwalska A., Rybakowski J. Zaburzenia psychiczne w chorobach tarczycy i nadnerczy. Psychiatr. Pol., 2001; 2: 273-283.
43. Irwin R., Ellis P.M. Psychosis following acute alteration of thyroid status. Aust. N. Z. J. Psychiatry, 1997; 31: 762-764.
44. Jarząb B., Płaczkiewicz-Jankowska E. Orbitopatia tarczycowa. W: Choroby wewnętrzne. Szczeklik A. red. Tom I. Kraków: Medycyna Praktyczna; 2005, s. 1057-1059.
45. Wiersinga W.M., Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid, 2002; 12: 855-860.
46. Putta-Manohar S., Perros P. Epidemiology of Graves' orbitopathy.Pediatr. Endocrinol. Rev., 2010; 7(Suppl 2): 182-185.
47. Dagi L.R., Elliott A.T., Roper-Hall G., Cruz O.A. Thyroid eye disease: honing your skills to improve outcomes. J. AAPOS, 2010; 14: 425-431.
48. Stiebel-Kalish H., Robenshtok E., Gaton D.D. Pathophysiology of Graves' ophthalmopathy. Pediatr. Endocrinol. Rev., 2010; 7(Suppl 2): 178-181.
49. Jastrzębska H. Postępy w rozpoznawaniu i leczeniu ciężkiej oftalmopatii tarczycowej. Postępy Nauk Medycznych, 2008; 2: 115-125.
50. Burch H.B., Wartofsky L. Graves’ ophthalmopathy: current concepts regarding the pathogenesis and management. Endocrine Reviews, 1993; 14: 747-793.
51. Terwee C., Wakelkamp I, Tan S., Dekker F., Prummel M.F.,Wiersinga W. Long-term effects of Graves’ ophthalmopathy on quality of life. Eur. J. Endocrinol., 2002; 146: 751-757.
52. Wiersinga W.M., Prummel M.F., Terwee C.B. Effects of Graves' ophthalmopathy on quality of life. J. Endocrinol. Invest., 2004; 27: 259-264.
53. Yeats R.P. Quality of life in patients with graves opthalmopathy. Transactions of the American Ophthalmological Society, 2005; 103: 368-411.
54. Park J., Sullivan T.J., Mortimer R.H., Wagenaar M., Perry-Keene D.A. Assessing quality of life in Australian patients with Graves’ ophthalmopathy. British Journal of Ophthalmology, 2004; 88: 75-78.
55. Warmuz-Stangierska I., Czarny W.A., Ziemnicka K., Stangierski R., Sowiński J. Jakość życia pacjentów z orbitopatią w przebiegu choroby Graves-Basedowa (kontynuacja badań). Przegl. Lek., 2004; 61: 857-859.
56. Terwee C.B., Gerding M.N., Dekker F.W., Prummel M.F., Wiersinga W.M. Development of a disease-specific quality of life question-naire for patients with Graves’ ophthalmopathy: the GO-QOL. British Journal of Ophthalmology, 1998; 82: 773-779.
57. Terwee1 C., Wakelkamp I., Tan S., Dekker F., Prummel M.F. Wiersinga W. Long-term effects of Graves’ ophthalmopathy on quality of life. Eur. J. Endocrinol., 2002; 146: 751-757.
58. Bartley G.B., Fatourechi V., Kadrmas E.F., Jacobsen S.J., Ilstrup D.M.,Garrity J.A. i wsp. Long-term follow-up of Graves’ ophthalmopathyin an incidence cohort. Ophthalmology, 1996; 103: 958-962.
59. Whybrow P.C., Prange Jr A.J., Treadway C.R. Mental changes accompanying thyroid gland dysfunction. Arch. Gen. Psychiatry, 1969; 20: 48-63.
60. Trzepacz P.T., McCue M., Klein I., Greenhouse J., Levey G.S. Psychiatric and neuropsychological response to propranolol in Graves’ disease. Biol. Psychiatry, 1988; 23: 678-688.
61. Bommer M., Eversmann T., Pickardt R., Leonhardt A., Naber D. Psychopatoholgical and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism. Klin. Wochenschr., 1990; 68: 552-558.
62. Stern R.A., Robinson B., Thorner A.R., i wsp. A survey study of neuropsychiatric complaints in patients with Graves’ disease. J. Neuropsychiatry Clin. Neurosci., 1996; 8: 181-185.
63. Boswell E.B. i wsp. Depression and physical illness. John Wiley and Sons Ltd.; 1997.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
